In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on BiomX (PHGE), with a price target of $28.00. The company’s shares closed last Tuesday at $6.50.
According to TipRanks.com, Nakae is a 5-star analyst with an average return of 26.0% and a 54.9% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Lineage Cell Therapeutics, and Arrowhead Pharmaceuticals.
BiomX has an analyst consensus of Moderate Buy, with a price target consensus of $24.00.
See today’s analyst top recommended stocks >>
Based on BiomX’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $8.84 million. In comparison, last year the company had a net profit of $56.99K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
